Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma

Table 1 Baseline characteristics of anaplastict thyroid cancer (ATC) patients treated with pembrolizumab added as a salvage therapy to kinase inhibitor therapy

	N = 12
Median Age at treatment start, years (range)	60 (47–84)
Gender, n (%)
Men Women	8 (67) 4 (33)
Ethnicity, n (%)
Caucasian Asian Black	9 (75) 2 (16) 1 (9)
Stage at Diagnosis, n (%)
IVA IVB IVC	0 (0) 3 (25) 9 (75)
Pathology, n (%)
ATC only Papillary thyroid cancer + ATC Poorly differentiated thyroid cancer + ATC Follicular thyroid cancer +ATC	4 (33) 4 (33) 3 (25) 1 (9)
PD-L1 status, n (%) < 10% 11–50% 51–100%	10 (83) 2 (20) 4 (40) 4 (40)
Performance Status, n (%)
ECOG 0 ECOG 1 ECOG 2	2 (16) 6 (50) 4 (33)
Previous Treatment for ATC, n (%)^a
Surgery, n (%) Radiation/chemosensitizing, n (%) Bridging Chemotherapy, n (%)^b	5 (41) 6 (50) 3 (25)
Targeted therapy^c, n (%)
Lenvatinib Dabrafenib + trametinib Trametinib alone	5 (41) 6 (50) 1 (9)

^aPatients received more than 1 modality of therapy
^bChemotherapy as a bridging therapy while awaiting targeted therapy
^cAll patients with BRAFV600E mutations were treated with dabrafenib + trametinib